FIGURE 3 from First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

Genes differentially expressed on treatment day 8 versus treatment baseline, as a function of TPST-1120 exposure. A, Linear associations of day 8 log₂ fold change in expression levels of indicated genes and TPST-1120 AUC₀–₂₄. All genes exhibited FDR P < 0.05 and effect size > 0.5. Data are shown for both TPST-1120 monotherapy (part 1) and TPST-1120 + nivolumab combination therapy (part 2). An AUC₀–₂₄ value of 66,180 ng⋅hour/mL was excluded as an outlier. B, Comparison of differential gene expression on day 8 as a function of AUC₀–₂₄ tertile. Median elevation magnitudes in highest tertile were statistically increased above baseline values (*, P < 0.05 by Wilcoxon pair-wise comparison).